The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.
Roche sees 'mid-single' digit sales growth in second half.
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
Financial terms of the acquisition were not disclosed.
Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.